Treatment of fibrosis with interleukin-11 antibody
US10865240B2 · kind B2 · utility
2Cited by
17References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 21, 2018 |
| Grant date | Dec 15, 2020 |
| Priority date | — |
| Expiry date | Jan 28, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.